Cardiac Science Inc.

The Irvine cardiac-device maker posted a net loss of $1.7 million, or 18 cents a share, for the third quarter, more than double the loss of $802,841, or 14 cents a share, for the same period last year. The company said research and development expenses for its Powerheart defibrillator-monitor, Cardiac Science’s first commercial product, totaled $1.1 million, about 65% of the third-quarter loss this year. The product is expected to be released later this year, Cardiac said. No revenue was reported.